Full development decision point

Sometimes the terms early and late clinical development are used instead of the phases 1, 2 and 3. Early development refers to all studies before the full development decision point, whereas late clinical development refers to all studies thereafter. 

FIGURE I Life cycle for new drug development. EIH, entry into humans FDDP, full development decision point. 

This point of interest is brought forward by the RISM approach to the structure of molecular liquids, and a RISM model with HNC closure supports a similar result for the excess chemical potential in terms of atom-atom correlations (Singer and Chandler, 1985 Hirata, 1998). RISM - reference interaction site model - is an acronym that refers to a class of theories for the joint two-atom distributions in molecular liquids. The most basic decision of RISM models is that theories of molecular liquids should focus first on the atom-atom distributions extracted from X-ray and neutron scattering data rather than more complex possibilities this highly practical point was not so obvious in an earlier epoch when models of molecular liquids were scarcely realistic on an atomic scale. That basic decision was encapsulated by invention of a site-site (or atom-atom) Ornstein-Zernike (SSOZ) (Cummings and Stell, 1982) equation that involved intramolecular atom-atom correlations. The original suggestions (Chandler and Andersen, 1972) were sufficiently successful as to support subsequent flamboyant developments, and to be substantially impervious to more fundamental improvements (Chandler et al, 1982). For these reasons a full discussion of the RISM models wouldn t fit here. Fortunately, a devoted exposition of current RISM work is already available (Hirata, 1998). 

The application of uncertainty factors in the revision of the RfD should be based on a thorough quantitative and qualitative evaluation of the full range of uncertainties and limitations of the critical smdies. Uncertainty factors apphed in the development of a revised RfD should include data-base insufficiency and interindividual toxicokinetic variabihty in dose reconstmction. As a starting point, an uncertainty factor of 2-3 should be applied to a central tendency estimate of dose derived from maternal hair, or a factor of about 2 should be applied to a central tendency estimate of dose derived from cord blood to account for inlerindividual pharmacokinetic variabihty in dose reconstractioa The choice of an uncertainty factor for data-base insufficiency is, in part, a policy decision however, given the data indicating possible low-dose sequelae and latent effects and immunotoxicity and cardiovascular effects, the... 

This economical test exposes die climatically unstable points of electronic components. Due to the nature of the test, the entire board is evaluated. This test accelerates the mechanisms of electrochemical migration. Consequently, faults that previously would appear after months or even years can be detected during the development process. To identify potential weak points, the assembly is operated in standby mode and immersed in deionized water. Testing while the assembly is in full operation is even more effective. The sensitivity of the circuit to moisture exposure is assessed on the basis of flie recorded test current, combined with a subsequent examination of the assembly. Through weak point analysis, a Yes/No decision can be determined concerning the expected service life, of the assembly. 

---